<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735475</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-USF-07-41</org_study_id>
    <nct_id>NCT00735475</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine</brief_title>
  <official_title>A Phase IV, Randomized, Observer-Blind, Multi-Center, Non Inferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Inactivated Split-Virion Influenza Vaccine in Adults Aged Greater Than or Equal to 65 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the immunogenicity and safety profile of CSL
      Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus
      Vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer 21 Days After the Study Vaccination</measure>
    <time_frame>21 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion 21 Days After the Study Vaccination</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>Seroconversion rate was defined as the proportion of participants with a HI titer of less than 1:10 before vaccination achieving a HI antibody titer of 1:40 or more after vaccination, or with a HI titer of 1:10 or more before vaccination achieving a four-fold or greater increase in HI titer after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Local and Systemic Solicited Symptoms</measure>
    <time_frame>5 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Local and Systemic Solicited Symptoms</measure>
    <time_frame>5 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Unsolicited Adverse Events (UAEs)</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>Abbreviation UAE stands for Unsolicited Adverse Event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>180 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Onsets of Chronic Illness</measure>
    <time_frame>180 days after vaccination</time_frame>
    <description>A NOCI was defined as the diagnosis of a chronic medical condition where the symptoms commenced or worsened following exposure to the study vaccine and may have included those potentially controllable by medication (e.g., glaucoma, hypertension).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1268</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Afluria®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL Limited Influenza Virus Vaccine (Afluria®)</intervention_name>
    <description>A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.</description>
    <arm_group_label>Afluria®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US Licensed Influenza Virus Vaccine (Fluzone®)</intervention_name>
    <description>A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.</description>
    <arm_group_label>Fluzone®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males aged ≥ 65 years or females of non-childbearing potential aged ≥ 65 years ;

          2. Written informed consent ;

          3. Willingness to provide a blood sample.

        Exclusion Criteria:

          1. Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs,
             chicken protein, neomycin, polymyxin, or any components of the Study Vaccines;

          2. Previous vaccination against influenza in 2008 or 2009 with seasonal trivalent
             inactivated influenza vaccine;

          3. Known history of Guillain-Barré Syndrome;

          4. Clinical signs of active infection and/or an oral temperature of greater than or equal
             to 100 degrees F (37.8 degrees C).

          5. Have active or recent and clinically significant gastrointestinal/hepatic, renal,
             neurological, cardiovascular, respiratory, endocrine disorders or other medical
             disorders;

          6. History of seizures;

          7. Confirmed or suspected immunosuppressive condition, or a previously diagnosed
             immunodeficiency disorder;

          8. Clinically significant history of malignancy

          9. Current treatment, or treatment with radiotherapy or cytotoxic drugs at any time
             during the six months prior to administration of the Study Vaccine;

         10. Current immunosuppressive or immunomodulative therapy;

         11. Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the administration of the Study Vaccine;

         12. Participation in a clinical trial or use of an investigational compound within 30 days
             prior to receiving the Study Vaccine ;

         13. Vaccination with a registered vaccine within 14 days (for inactivated vaccines) or 28
             days (for live vaccines) prior to receiving the Study Vaccine.

         14. Current treatment with warfarin or other anticoagulants;

         15. Major congenital defects;

         16. Evidence, or history (within the previous 12 months) of drug or alcohol abuse;

         17. Unwillingness or inability to comply with the study protocol including completion of
             adverse event diary cards;

         18. History of psychiatric disorders;

         19. Resident of long term care facility.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Director Vaccines</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Central Arkansas Medical Association</name>
      <address>
        <city>Mountain Home</city>
        <state>Arkansas</state>
        <zip>72635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance CRU, Inc</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/ Adult Research</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester School of Medicine and Dentistry</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance CRU, Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Physicians Research, Inc.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance CRU Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <results_first_submitted>July 3, 2011</results_first_submitted>
  <results_first_submitted_qc>August 2, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 1, 2011</results_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Afluria® Group</title>
          <description>Participants received one dose of the 2008/2009 formulation of Afluria® by intramuscular injection.</description>
        </group>
        <group group_id="P2">
          <title>Fluzone® Group</title>
          <description>Participants received one dose of the 2008/2009 formulation of Fluzone® by intramuscular injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="631"/>
                <participants group_id="P2" count="637"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="623"/>
                <participants group_id="P2" count="626"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Afluria® Group</title>
          <description>Participants received one dose of the 2008/2009 formulation of Afluria® by intramuscular injection.</description>
        </group>
        <group group_id="B2">
          <title>Fluzone® Group</title>
          <description>Participants received one dose of the 2008/2009 formulation of Fluzone® by intramuscular injection.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="630"/>
            <count group_id="B2" value="636"/>
            <count group_id="B3" value="1266"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Note: two participants (one in each group) did not provide follow-up safety information. Therefore, they are not included in the Safety Population.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="630"/>
                    <measurement group_id="B2" value="636"/>
                    <measurement group_id="B3" value="1266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.7" spread="5.56"/>
                    <measurement group_id="B2" value="71.7" spread="5.53"/>
                    <measurement group_id="B3" value="71.7" spread="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="364"/>
                    <measurement group_id="B2" value="362"/>
                    <measurement group_id="B3" value="726"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="274"/>
                    <measurement group_id="B3" value="540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="630"/>
                    <measurement group_id="B2" value="636"/>
                    <measurement group_id="B3" value="1266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer 21 Days After the Study Vaccination</title>
        <time_frame>21 days after vaccination</time_frame>
        <population>Evaluable Population: comprised participants who were vaccinated, provided blood samples before and after vaccination, did not experience a laboratory-confirmed influenza infection, and did not receive a contraindicated medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Afluria® by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Fluzone® by intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer 21 Days After the Study Vaccination</title>
          <population>Evaluable Population: comprised participants who were vaccinated, provided blood samples before and after vaccination, did not experience a laboratory-confirmed influenza infection, and did not receive a contraindicated medication.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="622"/>
                <count group_id="O2" value="630"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (A/Brisbane/59/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.60" lower_limit="53.35" upper_limit="64.37"/>
                    <measurement group_id="O2" value="58.45" lower_limit="53.23" upper_limit="64.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (A/Uruguay/716/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="377.94" lower_limit="339.31" upper_limit="420.97"/>
                    <measurement group_id="O2" value="337.23" lower_limit="302.99" upper_limit="375.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (B/Florida/4/2006)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.16" lower_limit="27.70" upper_limit="32.84"/>
                    <measurement group_id="O2" value="33.31" lower_limit="30.54" upper_limit="36.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion 21 Days After the Study Vaccination</title>
        <description>Seroconversion rate was defined as the proportion of participants with a HI titer of less than 1:10 before vaccination achieving a HI antibody titer of 1:40 or more after vaccination, or with a HI titer of 1:10 or more before vaccination achieving a four-fold or greater increase in HI titer after vaccination.</description>
        <time_frame>21 days after vaccination</time_frame>
        <population>Evaluable Population: comprised participants who were vaccinated, provided blood samples before and after vaccination, did not experience a laboratory-confirmed influenza infection, and did not receive a contraindicated medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Afluria® by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Fluzone® by intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion 21 Days After the Study Vaccination</title>
          <description>Seroconversion rate was defined as the proportion of participants with a HI titer of less than 1:10 before vaccination achieving a HI antibody titer of 1:40 or more after vaccination, or with a HI titer of 1:10 or more before vaccination achieving a four-fold or greater increase in HI titer after vaccination.</description>
          <population>Evaluable Population: comprised participants who were vaccinated, provided blood samples before and after vaccination, did not experience a laboratory-confirmed influenza infection, and did not receive a contraindicated medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="622"/>
                <count group_id="O2" value="630"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (A/Brisbane/59/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" lower_limit="34.7" upper_limit="42.5"/>
                    <measurement group_id="O2" value="43.2" lower_limit="39.3" upper_limit="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (A/Uruguay/716/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="65.2" upper_limit="72.6"/>
                    <measurement group_id="O2" value="68.7" lower_limit="64.9" upper_limit="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (B/Florida/4/2006)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="25.4" upper_limit="32.7"/>
                    <measurement group_id="O2" value="33.8" lower_limit="30.1" upper_limit="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Local and Systemic Solicited Symptoms</title>
        <time_frame>5 days after vaccination</time_frame>
        <population>Safety Population: comprised all participants who received study vaccine and provided safety follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Afluria® by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Fluzone® by intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Local and Systemic Solicited Symptoms</title>
          <population>Safety Population: comprised all participants who received study vaccine and provided safety follow-up safety data.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="630"/>
                <count group_id="O2" value="636"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2"/>
                    <measurement group_id="O2" value="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                    <measurement group_id="O2" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Local and Systemic Solicited Symptoms</title>
        <time_frame>5 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Afluria® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Afluria® by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Fluzone® by intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Local and Systemic Solicited Symptoms</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="630"/>
                <count group_id="O2" value="636"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="2.094"/>
                    <measurement group_id="O2" value="1.70" spread="2.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="2.147"/>
                    <measurement group_id="O2" value="1.90" spread="1.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.692"/>
                    <measurement group_id="O2" value="2.67" spread="1.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="3.031"/>
                    <measurement group_id="O2" value="2.25" spread="2.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.50" spread="8.021"/>
                    <measurement group_id="O2" value="10.50" spread="9.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="3.004"/>
                    <measurement group_id="O2" value="1.70" spread="1.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="1.850"/>
                    <measurement group_id="O2" value="2.08" spread="1.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" spread="3.193"/>
                    <measurement group_id="O2" value="2.65" spread="3.961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.737"/>
                    <measurement group_id="O2" value="2.29" spread="4.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="1.193"/>
                    <measurement group_id="O2" value="1.78" spread="0.972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Unsolicited Adverse Events (UAEs)</title>
        <description>Abbreviation UAE stands for Unsolicited Adverse Event.</description>
        <time_frame>21 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Afluria® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Afluria® by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Fluzone® by intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Unsolicited Adverse Events (UAEs)</title>
          <description>Abbreviation UAE stands for Unsolicited Adverse Event.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="630"/>
                <count group_id="O2" value="636"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with at least one UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants reported Grade 1 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants reported Grade 2 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants reported Grade 3 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <time_frame>180 days after vaccination</time_frame>
        <population>Safety Population: comprised all participants who received study vaccine and provided safety follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Afluria® by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Fluzone® by intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <population>Safety Population: comprised all participants who received study vaccine and provided safety follow-up safety data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="630"/>
                <count group_id="O2" value="636"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with at least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Onsets of Chronic Illness</title>
        <description>A NOCI was defined as the diagnosis of a chronic medical condition where the symptoms commenced or worsened following exposure to the study vaccine and may have included those potentially controllable by medication (e.g., glaucoma, hypertension).</description>
        <time_frame>180 days after vaccination</time_frame>
        <population>Safety Population: comprised all participants who received study vaccine and provided safety follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Afluria® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Afluria® by intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>Fluzone® Group</title>
            <description>Participants received one dose of the 2008/2009 formulation of Fluzone® by intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>New Onsets of Chronic Illness</title>
          <description>A NOCI was defined as the diagnosis of a chronic medical condition where the symptoms commenced or worsened following exposure to the study vaccine and may have included those potentially controllable by medication (e.g., glaucoma, hypertension).</description>
          <population>Safety Population: comprised all participants who received study vaccine and provided safety follow-up safety data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="630"/>
                <count group_id="O2" value="636"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with at least one NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with related NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasms benign, maligant and unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and connective tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and urinary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive system and breast disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs were collected up to 180 days after the study vaccination. Other adverse events were unsolicited adverse events that were collected up to 21 days after the study vaccination.</time_frame>
      <desc>Other Adverse Events reported were unsolicited adverse events that were collected up to 21 days after the study vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Afluria® Group</title>
          <description>Participants received one dose of the 2008/2009 formulation of Afluria® by intramuscular injection.</description>
        </group>
        <group group_id="E2">
          <title>Fluzone® Group</title>
          <description>Participants received one dose of the 2008/2009 formulation of Fluzone® by intramuscular injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="630"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Pubic rami fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Non-samall cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage IIIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Calculus baddder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="630"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="630"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="630"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="630"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="630"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="630"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="630"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="630"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="630"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="630"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="43" subjects_affected="33" subjects_at_risk="630"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="630"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="630"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="636"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="630"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="636"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Study Disclosure Manager</name_or_title>
      <organization>Seqirus</organization>
      <phone>1-855-358-8966</phone>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

